Bulletin
Investor Alert

Market Pulse Archives

Aug. 21, 2019, 7:42 a.m. EDT

Cerecor stock soars 17% premarket after FDA grants fast-track designation to treatment for rare disorder

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Cerecor Inc. (CERC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Shares of Cerecor Inc. /zigman2/quotes/201368871/composite CERC -0.99% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S. Food and Drug Administration has awarded it an expedited review process for a treatment for Mannose-Phosphate Isomerase Deficiency, or MPI-CDG, a rare metabolic disorder. The FDA has granted Rockville, Md.-based Cerecor Fast Trace Designation for its CERC-802 treatment, an oral formulation of D-mannose. CERC-802 is an ultra-pure formulation of D-mannose, a naturally occurring monosaccharide that is found in animals, microorganisms, and plants, including edible fruits and herbs. "CDG patients are born with a genetic defect that hinders their ability to utilize certain monosaccharides in the production of glycoproteins," the company explained. Shares have gained 19% in 2019, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.77% has gained 16%.

/zigman2/quotes/201368871/composite
US : U.S.: Nasdaq
$ 2.99
-0.03 -0.99%
Volume: 104,645
Nov. 15, 2019 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$131.88 million
Rev. per Employee
$286,356
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,120.46
+23.83 +0.77%
Volume: 1.87B
Nov. 15, 2019 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.